Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by Tumbleweed1on Mar 10, 2009 12:16am
385 Views
Post# 15832291

Phase 3

Phase 3Over the past half dozen-years or so, Brad has indicated from time-to-time that ONC is in discussion(s) with a major, or a number of majors. Be that as it may, I have suspected for some time now that ONC is in talks for two primary reasons. The first being to appear to be genuinely interested in partnering, possible to keep the majors at bay while searching for a suitable White Knight that is both able and willing to rescue the company in the event of a hostile takeover, and secondly to allow time for this small company to complete one phase three success and possibly registration before it acquires a distributer as well as adequte manufacturing facilities capable of supplying the quantities of Reolysin required to complete trials and eventually the release of the product to the market. That could provide funds for present and future trails.  
 
I also wonder what Brad and company are thinking at this time, with Texas and Ohio stepping up to bat. Are these and other US university research centres both capable and willing to run phase three trials?  Pehaps as a joint venture? If they are, does Brad need a partner, perhaps just a distributer would do. I can visualize the excitement generating within vareous University scientific communiities as these and other US Universities dream of banner headlines proclaiming that the University of Texas, Ohio, etc. has discovered a viable treatment for many cancers and possibly a cure for some. Think of the prestige, the grants, the funding, and possibly the Nobel Laureate, or is that spoken for?  

Just musing, and before you ask, I do have life, thank you


Tumbleweed           
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse